Cargando…

Which Vitamin D in CKD-MBD? The Time of Burning Questions

Vitamin D is a common treatment against secondary hyperparathyroidism in renal patients. However, the rationale for the prescription of vitamin D sterols in chronic kidney disease (CKD) is rapidly increasing due to the coexistence of growing expectancies close to unsatisfactory evidences, such as (1...

Descripción completa

Detalles Bibliográficos
Autores principales: Galassi, Andrea, Bellasi, Antonio, Auricchio, Sara, Papagni, Sergio, Cozzolino, Mario
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3749554/
https://www.ncbi.nlm.nih.gov/pubmed/23991423
http://dx.doi.org/10.1155/2013/864012
_version_ 1782477020172648448
author Galassi, Andrea
Bellasi, Antonio
Auricchio, Sara
Papagni, Sergio
Cozzolino, Mario
author_facet Galassi, Andrea
Bellasi, Antonio
Auricchio, Sara
Papagni, Sergio
Cozzolino, Mario
author_sort Galassi, Andrea
collection PubMed
description Vitamin D is a common treatment against secondary hyperparathyroidism in renal patients. However, the rationale for the prescription of vitamin D sterols in chronic kidney disease (CKD) is rapidly increasing due to the coexistence of growing expectancies close to unsatisfactory evidences, such as (1) the lack of randomized controlled trials (RCTs) proving the superiority of any vitamin D sterol against placebo on patients centered outcomes, (2) the scanty clinical data on head to head comparisons between the multiple vitamin D sterols currently available, (3) the absence of RCTs confirming the crescent expectations on nutritional vitamin D pleiotropic effects even in CKD patients, (4) the promising effects of vitamin D receptors activators (VDRA) against proteinuria and myocardial hypertrophy in diabetic CKD cohorts, and (5) the conflicting data on the impact on mortality of VDRA versus calcimimetic centered regimens to control CKD-MBD. The present review arguments these issues focusing on the opened questions that nephrologists should consider dealing with the prescription of nutritional vitamin D or VDRA and with the choice of a VDRA versus a calcimimetic based regimen in CKD-MBD patients.
format Online
Article
Text
id pubmed-3749554
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-37495542013-08-29 Which Vitamin D in CKD-MBD? The Time of Burning Questions Galassi, Andrea Bellasi, Antonio Auricchio, Sara Papagni, Sergio Cozzolino, Mario Biomed Res Int Review Article Vitamin D is a common treatment against secondary hyperparathyroidism in renal patients. However, the rationale for the prescription of vitamin D sterols in chronic kidney disease (CKD) is rapidly increasing due to the coexistence of growing expectancies close to unsatisfactory evidences, such as (1) the lack of randomized controlled trials (RCTs) proving the superiority of any vitamin D sterol against placebo on patients centered outcomes, (2) the scanty clinical data on head to head comparisons between the multiple vitamin D sterols currently available, (3) the absence of RCTs confirming the crescent expectations on nutritional vitamin D pleiotropic effects even in CKD patients, (4) the promising effects of vitamin D receptors activators (VDRA) against proteinuria and myocardial hypertrophy in diabetic CKD cohorts, and (5) the conflicting data on the impact on mortality of VDRA versus calcimimetic centered regimens to control CKD-MBD. The present review arguments these issues focusing on the opened questions that nephrologists should consider dealing with the prescription of nutritional vitamin D or VDRA and with the choice of a VDRA versus a calcimimetic based regimen in CKD-MBD patients. Hindawi Publishing Corporation 2013 2013-08-07 /pmc/articles/PMC3749554/ /pubmed/23991423 http://dx.doi.org/10.1155/2013/864012 Text en Copyright © 2013 Andrea Galassi et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Galassi, Andrea
Bellasi, Antonio
Auricchio, Sara
Papagni, Sergio
Cozzolino, Mario
Which Vitamin D in CKD-MBD? The Time of Burning Questions
title Which Vitamin D in CKD-MBD? The Time of Burning Questions
title_full Which Vitamin D in CKD-MBD? The Time of Burning Questions
title_fullStr Which Vitamin D in CKD-MBD? The Time of Burning Questions
title_full_unstemmed Which Vitamin D in CKD-MBD? The Time of Burning Questions
title_short Which Vitamin D in CKD-MBD? The Time of Burning Questions
title_sort which vitamin d in ckd-mbd? the time of burning questions
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3749554/
https://www.ncbi.nlm.nih.gov/pubmed/23991423
http://dx.doi.org/10.1155/2013/864012
work_keys_str_mv AT galassiandrea whichvitamindinckdmbdthetimeofburningquestions
AT bellasiantonio whichvitamindinckdmbdthetimeofburningquestions
AT auricchiosara whichvitamindinckdmbdthetimeofburningquestions
AT papagnisergio whichvitamindinckdmbdthetimeofburningquestions
AT cozzolinomario whichvitamindinckdmbdthetimeofburningquestions